KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

A Post-Hoc Analysis of Emotional Lability With Delayed-Release/Extended-Release Methylphenidate in Children Aged 6 to 12 Years of Age Participating in Two Phase 3 Clinical Trials.

Valerie K Arnold, Frank A López, Ann C Childress, Michelle D Po, Cassandra L Uchida, Lewis Cuthbertson, Floyd R Sallee, Bev Incledon

J Atten Disord 28(8) 1186-1197

PMID38600754
PMCIDPMC11107132
DOI10.1177/10870547241243155
发表日期2024-04-11
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

OBJECTIVE: DR/ER-MPH (formerly HLD200) is an evening-dosed delayed-release and extended-release methylphenidate approved for the treatment of ADHD in patients ≥6 years. Post hoc analyses of two pivotal Phase 3 trials: HLD200-107 (NCT02493777) and HLD200-108 (NCT02520388) evaluated emotional lability (EL) with DR/ER-MPH treatment. METHODS: Differences in Conners Global Index-Parent (CGI-P) EL subscale scores and age- and gender-adjusted T-scores over an open-label titration phase (HLD200-107) and between treatment and placebo groups at endpoint (HLD200-108) were evaluated. RESULTS: In HLD200-107 (N = 117) mean CGI-P EL subscale scores improved from 5.3 to 1.3 (p < .0001) after 6 weeks; in HLD200-108 significant improvements were observed in the treatment group (n = 81) versus placebo (n = 80; 3.11 vs. 4.08; p = .0053). T-scores showed an improvement with DR/ER-MPH treatment in both trials. Few emotional adverse events (AEs) were reported. CONCLUSION: DR/ER-MPH treatment resulted in statistically significant improvements in EL to the level of non-ADHD peers as contextualized by T-scores.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。